L-Glutamine Treats Non-Alcoholic Fatty Liver Disease in rats
Related Articles |
Objective Observe the effect of L-Glutamine on fat- induced nonalcoholic fatty liver disease (NAFLD) in rat. Methods Rats were randomly divided into control group, model group and L-glutamine treatment group, model group and L-glutamine treatment group build nonalcoholic fatty liver disease model after the high-fat diet, modeling success given the appropriate treatment, after 8 weeks, rats were sacrificed to detect relevant indicators. Results Treatment group compared with the model group were significantly changed, liver histology treated group compared with the model group significantly reduced, fat vacuoles reduced; LDL, AST, TBA CHOL, TG, LDL-C, IL-6, TNF-α, IL-α, IL-β, MDA and CRP treatment group compared with the model group was significantly lower (P<0.05); GSH, T-AOC , HDL-C was significantly higher (P<0.05); SREBF1 ACCα and mRNA and protein expression was significantly decreased (P<0.05), PPARα mRNA and protein expression was significantly increased(P<0.05). Conclusion L-glutamine can alleviate the symptoms of nonalcoholic fatty liver disease in rats, the mechanism may be by reducing SREBF1 and ACCα expression, while promoting PPARα expression achieved.